ATE314859T1 - Botulinumtoxine zur verstärkung der wundheilung - Google Patents
Botulinumtoxine zur verstärkung der wundheilungInfo
- Publication number
- ATE314859T1 ATE314859T1 AT99960130T AT99960130T ATE314859T1 AT E314859 T1 ATE314859 T1 AT E314859T1 AT 99960130 T AT99960130 T AT 99960130T AT 99960130 T AT99960130 T AT 99960130T AT E314859 T1 ATE314859 T1 AT E314859T1
- Authority
- AT
- Austria
- Prior art keywords
- wound healing
- botulinum toxins
- increase wound
- wound
- increase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10568898P | 1998-10-27 | 1998-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE314859T1 true ATE314859T1 (de) | 2006-02-15 |
Family
ID=22307238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99960130T ATE314859T1 (de) | 1998-10-27 | 1999-10-15 | Botulinumtoxine zur verstärkung der wundheilung |
Country Status (12)
Country | Link |
---|---|
US (3) | US6447787B1 (de) |
EP (1) | EP1128844B1 (de) |
JP (1) | JP2002528421A (de) |
KR (1) | KR20010089347A (de) |
CN (1) | CN1324246A (de) |
AT (1) | ATE314859T1 (de) |
AU (1) | AU1706400A (de) |
BR (1) | BR9914891A (de) |
CA (1) | CA2347828A1 (de) |
DE (1) | DE69929361T2 (de) |
MX (1) | MXPA01004254A (de) |
WO (1) | WO2000024419A1 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6276072B1 (en) * | 1997-07-10 | 2001-08-21 | Applied Materials, Inc. | Method and apparatus for heating and cooling substrates |
KR20010089347A (ko) * | 1998-10-27 | 2001-10-06 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 상처 치료 증진 방법 |
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
IL153734A0 (en) * | 2000-06-28 | 2003-07-06 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
DK1301213T3 (en) | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
DK1411978T3 (da) * | 2001-07-27 | 2009-01-05 | Univ Louisiana State | Botulinum-toksin ved behandlingen eller forebyggelsen af acne |
EA006739B1 (ru) * | 2001-11-15 | 2006-04-28 | Майкроу Элджи Корпорейшн | Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
CN100525831C (zh) * | 2002-12-20 | 2009-08-12 | 肉毒素研究同仁股份有限公司 | 改进的药用肉毒杆菌毒素组合物 |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US7670608B2 (en) * | 2003-03-06 | 2010-03-02 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
MXPA06009897A (es) * | 2004-03-03 | 2008-02-07 | Revance Therapeutics Inc | Composiciones y metodos para el diagnostico topico y el transporte terapeutico. |
MXPA06009898A (es) * | 2004-03-03 | 2008-02-07 | Revance Therapeutics Inc | Composiciones y metodos para la aplicacion topica y suministro transdermico de toxinas botulinicas. |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
US8377951B2 (en) * | 2004-05-07 | 2013-02-19 | Phytotox Limited | Transdermal administration of phycotoxins |
CN1997373B (zh) * | 2004-05-07 | 2010-12-22 | 菲特托克斯有限公司 | 藻毒素及其用途 |
US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US20060067950A1 (en) * | 2004-09-27 | 2006-03-30 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins for use in wound healing |
US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
GB0427642D0 (en) * | 2004-12-16 | 2005-01-19 | Renovo Ltd | Information collection system |
FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
KR101453963B1 (ko) | 2005-03-03 | 2014-10-22 | 레반스 테라퓨틱스, 아이엔씨. | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법 |
WO2006119499A2 (en) * | 2005-05-05 | 2006-11-09 | Phytotox Limited | Use of phycotoxins in veterinary applications |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US20060269574A1 (en) * | 2005-05-31 | 2006-11-30 | De Beer Johann F | Method of repairing tendons by surgery |
US8518414B2 (en) * | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
US20070178666A1 (en) * | 2006-01-31 | 2007-08-02 | Stats Chippac Ltd. | Integrated circuit system with waferscale spacer system |
US7414310B2 (en) * | 2006-02-02 | 2008-08-19 | Stats Chippac Ltd. | Waferscale package system |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
BRPI0720730A2 (pt) * | 2006-12-29 | 2014-04-08 | Revance Therapeutics Inc | Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat. |
JP2010514779A (ja) * | 2006-12-29 | 2010-05-06 | ルバンス セラピュティックス インク. | 逆配列hiv−tatポリペプチドを用いる輸送分子 |
LT2178549T (lt) | 2007-07-26 | 2017-01-25 | Revance Therapeutics, Inc. | Antimikrobinis peptidas ir jo kompozicijos |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
KR101258336B1 (ko) | 2008-10-02 | 2013-04-25 | 밀란 인크. | 다층 접착제 라미네이트를 제조하는 방법 |
CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
WO2011038015A1 (en) | 2009-09-24 | 2011-03-31 | Allergan, Inc. | Method of treating osteoporosis with a neurotoxin |
US20130123647A1 (en) | 2011-05-03 | 2013-05-16 | The Research Foundation Of State University Of New York | Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
AU2012276512B2 (en) * | 2011-06-27 | 2016-04-21 | Sang Duck Kim | Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US10076558B2 (en) * | 2014-02-18 | 2018-09-18 | Rnw Skn, Llc | Prophylactic normalization of cutaneous wound repair |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
SG11201701619TA (en) * | 2014-09-02 | 2017-03-30 | American Silver Llc | Botulinum toxin and colloidal silver particles |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
US10272024B1 (en) | 2016-11-28 | 2019-04-30 | Muhammad Mirza | Methods for administration of cosmetic and medical agents |
EP3470054B1 (de) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Mikrostrukturformulierungstechniken für botulinumtoxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
US20190183987A1 (en) * | 2017-12-18 | 2019-06-20 | Bonti, Inc. | Neurotoxins for use in minimizing scarring |
LT3660509T (lt) | 2018-11-29 | 2022-05-10 | Hugel Inc. | Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966934A (en) * | 1971-12-08 | 1976-06-29 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
US3957996A (en) * | 1971-12-08 | 1976-05-18 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic compositions |
US4029794A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition |
US4029793A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
US4080448A (en) | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
JPS5594319A (en) * | 1979-01-09 | 1980-07-17 | Yoshio Otaka | Drug for external use consisting of liver oil of swellfish |
JP4249802B2 (ja) * | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
DE69620888T2 (de) * | 1996-11-27 | 2002-08-14 | William J. Binder | Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
KR20010089347A (ko) * | 1998-10-27 | 2001-10-06 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 상처 치료 증진 방법 |
-
1999
- 1999-10-15 KR KR1020017005176A patent/KR20010089347A/ko not_active Application Discontinuation
- 1999-10-15 BR BR9914891-9A patent/BR9914891A/pt not_active IP Right Cessation
- 1999-10-15 CN CN99812622A patent/CN1324246A/zh active Pending
- 1999-10-15 CA CA002347828A patent/CA2347828A1/en not_active Abandoned
- 1999-10-15 MX MXPA01004254A patent/MXPA01004254A/es unknown
- 1999-10-15 EP EP99960130A patent/EP1128844B1/de not_active Expired - Lifetime
- 1999-10-15 WO PCT/US1999/024182 patent/WO2000024419A1/en active IP Right Grant
- 1999-10-15 AT AT99960130T patent/ATE314859T1/de not_active IP Right Cessation
- 1999-10-15 JP JP2000578027A patent/JP2002528421A/ja active Pending
- 1999-10-15 DE DE69929361T patent/DE69929361T2/de not_active Expired - Lifetime
- 1999-10-15 AU AU17064/00A patent/AU1706400A/en not_active Abandoned
- 1999-10-15 US US09/807,793 patent/US6447787B1/en not_active Expired - Lifetime
-
2001
- 2001-11-26 US US09/995,022 patent/US20030036502A1/en not_active Abandoned
-
2005
- 2005-02-18 US US11/061,299 patent/US20060039930A2/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000024419A8 (en) | 2001-03-15 |
US20030036502A1 (en) | 2003-02-20 |
WO2000024419A9 (en) | 2001-09-20 |
US20050175637A1 (en) | 2005-08-11 |
WO2000024419A1 (en) | 2000-05-04 |
AU1706400A (en) | 2000-05-15 |
EP1128844A1 (de) | 2001-09-05 |
EP1128844A4 (de) | 2002-06-12 |
EP1128844B1 (de) | 2006-01-04 |
CA2347828A1 (en) | 2000-05-04 |
US6447787B1 (en) | 2002-09-10 |
JP2002528421A (ja) | 2002-09-03 |
CN1324246A (zh) | 2001-11-28 |
DE69929361D1 (de) | 2006-03-30 |
MXPA01004254A (es) | 2002-04-24 |
DE69929361T2 (de) | 2006-09-14 |
BR9914891A (pt) | 2001-07-17 |
KR20010089347A (ko) | 2001-10-06 |
US20060039930A2 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE314859T1 (de) | Botulinumtoxine zur verstärkung der wundheilung | |
DE60142839D1 (de) | Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln | |
PT880350E (pt) | Tratamento de esclerose multipla | |
ATE215832T1 (de) | Botulinumtoxin zur reduktion von migraine - kopfschmerzen | |
ATE206946T1 (de) | Vorrichtung zur therapeutischen behandlung von wunden | |
PT938326E (pt) | Fosfopeptidos de sintese para o tratamento de doencas dos ossos | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
BR0213100A (pt) | Combinações para o tratamento de distúrbios imuniinflamatórios | |
HK1037980A1 (en) | Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage. | |
PL373528A1 (en) | Medicine for preventing and treating bromidrosis | |
ATE275580T1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
ATE246924T1 (de) | Neue therapeutische verwendung von nicergoline | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
NO984197L (no) | FremgangsmÕte for behandling av autisme | |
ATE228840T1 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
DE59805246D1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
TR199801801T2 (xx) | Madde k�t�ye kullan�m�n�n tedavisi. | |
NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
DE60143278D1 (de) | Verfahren zur Vorbeugung oder Behandlung von Diabetes | |
ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
DE69030181D1 (de) | Verwendung von cromakalim/brl 38227 zur behandlung der überreaktivität der luftwege | |
NO984190L (no) | FremgangsmÕte for behandling av insomnia | |
RO87383B1 (ro) | Metoda de tratare a varicelor | |
UA38987A (uk) | Спосіб лікування піодермії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |